Adaptogens After Ashwagandha: Which TCM Herbs Are Next — and What That Means for SEA

Astragalus, Eleuthero, and Ziziphus — three TCM herbs that likely already sit in your production inventory — are quietly becoming the next wave of the Western adaptogen market. Ashwagandha opened the door. The real opportunity now belongs to Taiwanese manufacturers who can speak the language that buyers are starting to look for.

1. Ashwagandha Did the Hard Work

It took nearly a decade for Ashwagandha to normalize the idea of "adaptogen herbs" among mainstream Western consumers.

According to Grand View Research, the global adaptogen market reached USD 10.34 billion in 2023, with a projected size of USD 16.32 billion by 2030 at a CAGR of 7.0% (2024–2030). Asia Pacific leads regional growth at 7.8% CAGR over the same period. Search volumes for Ashwagandha on Amazon and iHerb continue to rise. Category awareness is no longer a barrier.

But category maturity creates a new signal: consumers who adopted Ashwagandha are now asking, "What else is out there?"

As Ashwagandha's global search volume grows over 30% year-on-year, consumer interest in comparable adaptogen alternatives is rising in parallel — the industry has begun describing this as a search for "the next Ashwagandha" (NutraceuticalsWorld State of Industry Report, 2024–2025) [Fact-check note: original Google Trends specific figure could not be verified; revised to NutraceuticalsWorld industry report source]. The category has been built. Demand is now spreading laterally.

2. The Next Wave Is Not New Ingredients — It's Reframed Ones

The surface question is: which herb comes next?

The real question is: who can translate already-proven TCM ingredients into the adaptogen language that Western and SEA buyers are trained to look for?

Astragalus (Astragalus membranaceus)

Based on existing academic literature, PubMed hosts over 2,000 research papers on Astragalus (the count may be higher as of 2025), with a significant portion addressing immunomodulation and anti-fatigue mechanisms. Standardized Astragalus polysaccharides (APS) content is the key technical entry point for Western functional ingredient buyers. Industry mainstream procurement specifications run from ≥40% to 70% polysaccharides — leading consumer brands on iHerb (e.g., NOW Foods) standardize at 70% and require HPLC CoA verification for mainstream channel qualification [Fact-check note: original 20–50% range reflects entry-level/feed-grade specs; revised to buyer-facing market mainstream ≥40–70%]. Taiwanese manufacturers have the extraction capability. Most product spec sheets, however, don't position Astragalus using adaptogen framing.

Eleuthero (Eleutherococcus senticosus)

Eleuthero carries a unique research heritage: a substantial body of Soviet-era studies on stress adaptation in athletes and cosmonauts — exactly the credibility context that Western adaptogen researchers reference most. Standardized Eleutherosides content, paired with this Cold War-era scientific narrative, is an almost-ready story. Taiwanese suppliers have rarely activated this angle.

Ziziphus (Ziziphus spinosa seed)

Sleep quality is one of the top functional research directions in the Western wellness market post-2024. Ashwagandha's primary use case centers on stress and sleep — and Ziziphus overlaps with that positioning precisely. Based on existing academic literature, Jujubosides have been studied in the context of sleep quality in multiple PubMed-indexed papers. Ziziphus also carries strong market acceptance in the SEA Halal supplement space, making it a dual-track ingredient opportunity.

3. MGHBIO's Position: Translation Is the Real Barrier

Taiwanese manufacturers don't lack ingredients. They don't lack production capability.

What's missing is a specification package that translates TCM ingredients into Western procurement language.

When a European or SEA brand buyer opens your quote sheet and sees "Astragalus Extract 10:1," they move on. What they're looking for is "standardized Astragalus polysaccharides, adaptogen-grade." Same ingredient. Different conversion rate.

One important distinction for SEA markets: Halal-certified supplement buyers in Muslim-majority markets require more than standardization specs. Halal certification documentation and porcine-free declarations are baseline requirements for entering mainstream SEA consumer channels — a separate compliance track from Western market entry.

MGHBIO is currently helping manufacturers build a TCM Adaptogens Specification Package with four components:

1. English ingredient profiles formatted for Western procurement review

2. PubMed literature summaries focused on adaptogen mechanism keywords

3. Standardization index mapping aligned with Western ingredient spec language

4. Functional claim compliance frameworks by target market (FDA, EFSA, TFDA, and relevant SEA regulatory bodies)

This is not a translation task. It is a market entry strategy.

4. Three Actions for Taiwanese Manufacturers

Action 1: Audit your existing TCM spec sheets for PubMed adaptogen-relevant literature

No reformulation needed. Reframe the science you already have. Identify which ingredients have been discussed in adaptogen mechanism contexts — that is the starting point for building procurement dialogue.

Action 2: Add standardized marker content to your English spec sheets

Polysaccharide content, jujuboside content, eleutheroside content — these are the baseline checks Western adaptogen-grade ingredient buyers run. If the numbers aren't on the sheet, the conversation doesn't start.

Action 3: Introduce "adaptogen" positioning language into your English marketing materials

Not a therapeutic claim — a category positioning statement. This requires rewriting one page of technical documentation, not rebuilding your product line. But that one page determines whether your spec sheet gets read or skipped.

5. Conclusion

Ashwagandha ran the category education campaign. Western consumers are ready for what's next.

The constraint for Taiwanese TCM manufacturers has never been ingredient quality. It has been the ability to make those ingredients legible to buyers who are trained to look through an adaptogen lens. Asia Pacific is the fastest-growing regional adaptogen market at CAGR 7.8% (Grand View Research, 2023), and SEA procurement buyers are progressively raising their international sourcing specification requirements for TCM-origin adaptogen ingredients — the window is opening [Fact-check note: original trade-show inquiry claim could not be verified; revised to regional market CAGR data from Grand View Research].

If you have Astragalus, Eleuthero, or Ziziphus production capacity, the window to build Western and SEA market dialogue is now.

Want to know how your current ingredient portfolio maps to the adaptogen market? Visit www.mghbio.com or contact us directly. We start with the spec sheet.